MedTrace Logo

Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.

NCT03889808 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2019-04-02

No results posted yet for this study

Summary

The objective of this study to evaluate the seroprevalence of anti-bodies against C. difficile toxins A and B and the asymptomatic carriage of C. difficile in IBD patients according to the need and type of immunosuppressive therapy. The ultimate goal is to identify, among IBD patients, those with the highest risk of CDI.

Conditions

  • Clostridium Difficile
  • Inflammatory Bowel Diseases

Interventions

DIAGNOSTIC_TEST

Determination of serum anti-toxin Abs for C. difficile

Sponsors & Collaborators

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Jordi Guardiola, MD · Hospital Universitari de Bellvitge

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2021-01-31
Completion
2021-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03889808 on ClinicalTrials.gov